SAN DIEGO, May 20, 2015 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $5.00 per share, before underwriting discounts, for an aggregate offering of $30 million. 493 more words
Tags » Hematopoietic Stem Cell Transplantation
BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel Stem Cell Mobilization Treatment
JERUSALEM–(BUSINESS WIRE)–BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today successful top-line results from the Phase 1 safety and efficacy study of its lead clinical candidate, BL-8040, as a novel approach for mobilization and collection of bone-marrow stem cells from the peripheral blood circulation. 1,105 more words
JERUSALEM–(BUSINESS WIRE)–BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has closed its previously announced underwritten public offering of 14,375,000 American Depositary Shares (“ADSs”), each representing ten (10) of its Ordinary Shares, at a public offering price of $2.00 per ADS, for gross proceeds of $28.75 million. 418 more words
Kumar G, Ahmad S, Taneja A, et al. Severe sepsis in hematopoietic stem cell transplant recipients*. Crit Care Med. 2015 Feb;43(2):411-21.